Cassella Aktiengesellschaft

Hoechst Aktiengesellschaft

Sanofi

Ajinomoto Co., Ltd.

Sanofi-a Ventis Deutschland Gmbh

Cassella Aktiengellschaft

Cassella Aktiengessellschaft

Sanofi-aventis

Hoechst Marion Roussel

Melitta Just

Helmut Bohn

Rudi Beyerle

Gerhard Zoller

Karl Schonafinger

Otmar Klingler

Bernd Jablonka

Wolfgang Konig

Jochen Knolle

Gerhard Breipohl

Piero A Martorana

Rolf-Eberhard Nitz

Tilo Weiss

Gerhard Hessler

Gernot Zech

Jorg Ostrowski

Werngard Czechtizky

Naoyuki Fukuchi

Joerg Czech

Hans-Ulrich Stilz

Kuniya Sakurai

Eckard Kujath

Marc Nazaré

Christian Baumgartner

Hans Ulrich Stilz

Marc Nazare

Jochen Goerlitzer

Sven Ruf

Markus Kohlmann

Anton Mogilev

SchoKarl

Wolfgang K Onig

The present invention relates to compounds of the formula I, in which R; R; R; R; R; R; Z; A; B; E; X; Q; J; V; G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable e.g. for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

Quinoline-carboxamide derivatives as P2Y12 antagonists

The present invention relates to compounds of the formula I, whereinR1; R2; Z; A; B; D; Q; J; V; G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable, e.g., for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

Pyrazole-carboxamide derivatives as P2Y12 antagonists

The present invention relates to compounds of the formula I, wherein

Heterocyclic pyrazole-carboxamidesas P2Y12 antagonists

The present invention relates to compounds of the formula I, in which R1; R2; R3; R4; R5; R6; R7; R8; R9; R10; R11; R12; R13; A; B, D and E have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong anti-aggregating effect on platelets and thus an anti-thrombotic effect and are suitable e.g. for the therapy and prophylaxis of cardio-vascular disorders like thromboembolic diseases or restenoses. They are reversible antagonists of the platelet ADP receptor P2Y12, and can in general be applied in conditions in which an undesired activation of the platelet ADP receptor P2Y12 is present or for the cure or prevention of which an inhibition of the platelet ADP receptor P2Y12 is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

Pyrrole derivatives as P2Y12 antagonists

The present invention relates to compounds of the formula I, in which R1, R2, A, B, D, E, n, m or o have the meanings indicated below. The compounds of the formula I are valuable pharmacologically active compounds. They are reversible inhibitors of the interaction between the plasma protein von Willebrand factor (vWF) and the blood platelet receptor glycoprotein Ib-IX-V complex (GPIb). They exhibit an antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of atherothrombotic diseases.

Inhibitors of the GPIb-vWF interaction, their preparation and use

The present invention relates to compounds of the formula I, in which R1, R2, A, B, D, F, n, m and o have the meanings indicated herein. The compounds of the formula I are valuable pharmacologically active compounds. They are reversible inhibitors of the interaction between the plasma protein von Willebrand factor (vWF) and the blood platelet receptor glycoprotein Ib-IX-V complex (GPIb). They exhibit an antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of atherothrombotic diseases 

Inhibitors of the GPIb&#x2014;vWF interaction, their preparation and use

5-Membered ring heterocycle of the formula I,

Substituted 5-membered ring heterocycles comprising a bicyclic or tricyclic group their preparation and their use

Substituted 5-membered ring heterocycles, their preparation and their use

Urea derivatives, their preparation and use

Hydantoin derivatives of the formula I ##STR1## in which n is 3 or 4, R.sup.1 is alkyl or a radical of the formula R'--NH--C.dbd.N--R' with R' and R' being hydrogen or alkyl, and R.sup.2 is hydrogen, --NH--CO--NH.sub.2 and optionally substituted alkyl, and a process for the preparation thereof and the use thereof for inhibiting platelet aggregation, are described.

Hydantoin derivates

Substituted amino compounds, their preparation and their use as

Heterocycles, their preparation and their use

The present invention relates to compounds of the general formula I ##STR1## in which R, R.sup.1 to R.sup.4, r, Y, Z and W are defined as indicated in the description, a process for their preparation and their use as inhibitors of platelet aggregation, metastasis of carcinoma cells and osteoclast binding to the bone surfaces.

Imidazolidine derivatives

Phenylimidazolidine derivatives of the general formula I ##STR1## in which, for example, Y denotes --CH.sub.2 --CH.sub.2 --CO--

Phenylimidazolidine derivatives and their use

Aspartic acid derivatives of the formula ##STR1## in which X denotes, for example, ##STR2## and R denotes, for example, cyclohexylamino, have useful pharmacological properties.

Aspartic acid derivatives, and their use for inhibiting platelete

Growing community of inventors

Langen, Germany

Melitta Just